NTRB_OUT_1 [2025-04-29 08:36:30 -0400] 5683 Bytes | 1563 tokens | Cum: 1563 tkns (19.54% of 8k)
==========================================================================

Booyah, my friends! It's already 8:36 AM on Tue Apr 29, 2025, and I've got my eyes locked on Nutriband (NTRB), pushing up to $5.84 from $5.32. Are we in for a serious bull run, or is this just hype? I've pulled the data—let's break it down!

--- COMPANY PROFILE ---
Company: Nutriband (NTRB)
IPO: 2017-06-20 (7 Years Ago)
Market Cap: $56,863,667
Shares Outstanding: 11,110,000
Industry: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES
Exchange: XNAS
Description: Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Here’s a list of headlines for Nutriband:

Apr-11-25 07:00AM - Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology
Apr-04-25 05:41PM - UPDATE Nutriband Signs Associate Partnership with Charlotte FC
Apr-04-25 05:41PM 07:00AM - Nutriband Signs Partnership Agreement with Charlotte FC
Feb-21-25 07:00AM - Nutriband Receives Certificate of Registration for Trademark covering Pharmaceutical and Product Research and Development.
Feb-13-25 07:00AM - Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa Fentanyl Abuse Deterrent Fentanyl Patch
Feb-11-25 09:00AM - Nutriband Inc. Announces Olympian Anastasia Nichita to Advisory Board
Feb-07-25 08:45AM - Nutriband Receives Notice Of Allowance For New U.S. Patent Covering Its Transdermal Abuse Deterrent Technology Aversa
Dec-31-24 07:00AM - Nutriband Issues Letter to Shareholders
Dec-28-24 09:30AM - Nutriband extends Chinese patent to Macao for AVERSA technology
Dec-27-24 09:25AM - Nutriband Extends Chinese Patent to Macao for its AVERSA Abuse Deterrent Transdermal Technology
Dec-04-24 09:00AM - Nutriband Inc. Quarterly Report Highlights Record Revenue for Q3 up 50.94% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Dec-04-24 09:00AM 07:00AM - Nutriband Inc. to Present at The 2024 Noble Conference in Boca Raton on December 4th
Nov-27-24 07:00AM - Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa Abuse Deterrent Transdermal Technology
Oct-31-24 08:35AM - Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
Oct-17-24 07:00AM - Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
Oct-02-24 07:00AM - Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
Sep-24-24 08:45AM - As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
Sep-24-24 08:45AM 07:00AM - Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Sep-20-24 06:50AM - Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
Sep-16-24 04:00PM - Nutriband Inc. Authorizes $1M Share Buyback Program
Sep-04-24 07:00AM - Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Jul-19-24 07:00AM - Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-04T11:00:00Z - Nutriband Signs Partnership Agreement with Charlotte FC
B2 - 2025-02-13T12:00:00Z - Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch
B3 - 2024-12-31T12:00:00Z - Nutriband Issues Letter to Shareholders
B4 - 2024-12-27T14:25:00Z - Nutriband Extends Chinese Patent to Macao for its AVERSA™ Abuse Deterrent Transdermal Technology
B5 - 2024-03-28T18:08:52Z - Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B6 - 2024-03-27T17:06:58Z - Why LuxUrban Hotels Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Nutriband (NTRB).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

NTRB_OUT_3 [2025-04-29 08:36:30 -0400] 895 Bytes | 236 tokens | Cum: 1801 tkns (22.51% of 8k)
==========================================================================

Showing B2 (chunk 1 of 1): B2:
**Nutriband and Kindeva Drug Delivery Formalize Exclusive Development Partnership for Aversa™ Fentanyl Abuse Deterrent Fentanyl Patch**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/02/13/3025743/0/en/Nutriband-and-Kindeva-Drug-Delivery-Formalize-Exclusive-Development-Partnership-for-Aversa-Fentanyl-Abuse-Deterrent-Fentanyl-Patch.htmlNutriband and Kindeva Drug Delivery have signed an exclusive partnership to develop Aversa™ Fentanyl, an abuse-deterrent fentanyl patch. The partnership involves shared development costs in exchange for milestone payments.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_5 [2025-04-29 08:36:31 -0400] 939 Bytes | 289 tokens | Cum: 2092 tkns (26.15% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-24T10:43:20Z - Nutriband (NTRB) Projected to Post Earnings on Tuesday...
A2 - 2025-04-23T05:58:37Z - Nutriband (NASDAQ:NTRB) Stock Price Up 1.4% - What's Next?...
A3 - 2025-04-11T11:55:13Z - Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology | Taiwan New...
A4 - 2025-04-11T11:00:47Z - Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology...
A5 - 2025-04-11T11:00:00Z - Nutriband Granted Patent in Macao for its AVERSA Abuse Deterrent Transdermal Technology | Business U...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

NTRB_OUT_7 [2025-04-29 08:36:34 -0400] 1181 Bytes | 354 tokens | Cum: 2448 tkns (30.60% of 8k)
==========================================================================

Showing A1 (chunk 1 of 3): A1:
**Nutriband (NTRB) Projected to Post Earnings on Tuesday**Date: 2025-04-25Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/nutriband-ntrb-projected-to-post-earnings-on-tuesday-2025-04-22/Nutriband (NASDAQ:NTRB - Get Free Report) will likely be announcing its earnings results before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $0.71 million for the quarter.

Shares of NTRB stock opened at $5.12 on Tuesday. The company has a market capitalization of $56.86 million, a price-to-earnings ratio of -7.21 and a beta of 1.19. Nutriband has a 12-month low of $3.20 and a 12-month high of $11.78. The firm has a fifty day moving average of $6.23 and a 200-day moving average of $5.78. The company has a quick ratio of 4.83, a current ratio of 4.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_9 [2025-04-29 08:36:35 -0400] 1181 Bytes | 265 tokens | Cum: 2715 tkns (33.94% of 8k)
==========================================================================

Showing A1 (chunk 2 of 3): 96 and a debt-to-equity ratio of 0.01.

Separately, Noble Financial started coverage on Nutriband in a research report on Wednesday, January 22nd. They set an "outperform" rating and a $13.00 price objective for the company.

Check Out Our Latest Stock Analysis on NTRB

Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or c

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_11 [2025-04-29 08:36:36 -0400] 853 Bytes | 197 tokens | Cum: 2914 tkns (36.43% of 8k)
==========================================================================

Showing A1 (chunk 3 of 3): omments about this story to [email protected].

Before you consider Nutriband, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.

While Nutriband currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_13 [2025-04-29 08:36:37 -0400] 1104 Bytes | 282 tokens | Cum: 3198 tkns (39.98% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-28 10-K ITEM 7. MGT DISC & ANALYSIS OF FIN COND & RESULTS OF OPER

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our CONS financial statements and related notes includ...

S2 - 2025-02-13 8-K Item 7.01. Regulation FD Disclosure.

Nutriband Inc., a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has signed an addendum to the Commercial Development and Clinical Supply Agrmt for its lead product, Aversa...

S3 - 2025-02-12 8-K Item 7.01. Regulation FD Disclosure.

On February 7, 2025, Nutriband Inc. announced that we have received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) on February 3, 2025 for patent application 18/369,241, "Abuse and Misuse Deterrent Transderm...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

NTRB_OUT_15 [2025-04-29 08:36:38 -0400] 1181 Bytes | 246 tokens | Cum: 3446 tkns (43.08% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this report. This discussion contains forward-looking statements that involve risks, uncertainties and assumptions. See Note Regarding Forward-Looking Statements. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of certain factors discussed in Risk Factors and elsewhere in this report.

Overview

AVERSA Abuse Deterrent Transdermal Products

Our primary business is the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is AVERSA Fentanyl, our abuse deterrent fentanyl transdermal sy

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_17 [2025-04-29 08:36:39 -0400] 1181 Bytes | 258 tokens | Cum: 3706 tkns (46.33% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): stem which will require approval from the Food and Drug Administration (FDA) and substantial capital for research and development. AVERSA Fentanyl has the potential to provide clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy combined with properties designed to deter the abuse and misuse of fentanyl patches. In addition, we believe that our abuse deterrent technology can be broadly applied to various other transdermal products and our strategy is to follow the development of our abuse deterrent fentanyl transdermal system with the development of abuse deterrent transdermal products for pharmaceuticals that have a risk of abuse, misuse or accidental exposure.

On September 19, 2023, the United States Patent and Trademark Office (USPTO) granted US Patent No. 11,759,431 for Nutribands pro

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_19 [2025-04-29 08:36:40 -0400] 1181 Bytes | 262 tokens | Cum: 3970 tkns (49.62% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): prietary AVERSA abuse deterrent technology utilizing taste aversion to address the primary routes of abuse of opioid based transdermal patches. The issuance of this patent, entitled, Abuse and Misuse Deterrent Transdermal Systems, further expands Nutribands intellectual property protection in the United States for its portfolio of AVERSA abuse deterrent transdermal products.

Transdermal Pharmaceutical Products

Through October 31, 2018, our business was the development of a line of consumer and health products that are delivered through a transdermal or topical patch. Following our acquisition of 4P Therapeutics on August 1, 2018, our focus expanded to include prescription pharmaceuticals, and we are seeking to develop and seek FDA approval on a number of transdermal pharmaceutical products under development by 4P Therapeutics.

Most of our planned consumer products require FDA approva

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_21 [2025-04-29 08:36:41 -0400] 1181 Bytes | 255 tokens | Cum: 4227 tkns (52.84% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): l for sale in the United States, and we have not sought to obtain, and we do not plan to seek to obtain, FDA approval to market these products in the United States at this time. Following our acquisition of selected assets from Pocono Coated Products, LLC (Pocono), we are primarily focused on providing contract manufacturing services and consulting services to third party brands with no intention at this time to launch our own consumer products.

4P Therapeutics has not generated any revenue from any of its products under development. Rather, prior to our acquisition, 4P Therapeutics generated revenue to provide cash for its operations through contract research and development and related services for a small number of clients in the life sciences field on an as-needed basis. We are, for the near term, continuing this activity, although we do not anticipate that it will generate signific

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_23 [2025-04-29 08:36:42 -0400] 1181 Bytes | 251 tokens | Cum: 4480 tkns (56.00% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): ant revenues and, since our acquisition, it has generated minor gross margins. We have no long-term contractual obligations, and either party can terminate at any time.

With the change in our focus, our capital requirements increased substantially. The process of developing pharmaceutical products and submitting them for FDA approval is both time consuming and expensive, with no assurance of obtaining approval from the FDA to market our product in the United States. We will require approximately $13 million for research and development of our abuse deterrent fentanyl transdermal system, including clinical manufacturing and clinical trials that need to be completed in order to obtain FDA approval. However, the total cost could be substantially in excess of that amount.

On March 20, 2024, our Board of Directors adopted an amendment to the Companys 2021 Employees Stock Option Plan (the Pl

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_25 [2025-04-29 08:36:42 -0400] 790 Bytes | 197 tokens | Cum: 4679 tkns (58.49% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): an) increasing the number of shares of common stock subject to the Plan (as of March 20, 2024) to 1,400,00 shares (the Amendment). The Plan adopted by the Board on November 1, 2021, provided for an initial 350,000 shares to issue and sell upon the exercise of stock options issued under the Plan.. We submitted the Amendment to the Plan to our stockholders for adoption and approval at the 2025 Annual Meeting, increasing the authorized number of shares of common stock available for issuance of options ...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

NTRB_OUT_27 [2025-04-29 08:36:50 -0400] 5866 Bytes | 1579 tokens | Cum: 6260 tkns (78.25% of 8k)
==========================================================================

This is our set of metrics for Nutriband.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+-----------------------+
| Volume: 53,938 | Perf Month: -11.11% | Option/Short: No / Yes | Sales Y/Y TTM: -3.18% |
+--------------------+-----------------------+------------------------+-----------------------+
| Avg Volume: 67.90K | Perf Quarter: -26.63% | Short Float: 3.57% | ROE: -80.83% |
+--------------------+-----------------------+------------------------+-----------------------+
| Rel Volume: 0.74 | Index: - | Short Ratio: 2.69 | ROI: -60.62% |
+--------------------+-----------------------+------------------------+-----------------------+
| RSI (14): 56.95 | Market Cap: 64.86M | Short Interest: 0.18M | Sales Surprise: - |
+--------------------+-----------------------+------------------------+-----------------------+
| ATR (14): 0.41 | Shs Outstand: 11.11M | Beta: 1.22 | EPS Surprise: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA20: 11.32% | Shs Float: 5.11M | Sales Q/Q: 50.94% | P/E: - |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA50: -5.40% | Inst Own: 2.21% | Sales past 5Y: 62.95% | Earnings: Dec 02 |
+--------------------+-----------------------+------------------------+-----------------------+
| SMA200: 0.43% | Insider Own: 54.01% | Employees: - | |
+--------------------+-----------------------+------------------------+-----------------------+
| Perf Week: 14.06% | Insider Trans: 0.00% | Debt/Eq: 0.02 | |
+--------------------+-----------------------+------------------------+-----------------------+

The next section covers any insider trading by Nutriband officers or majority shareholders (if available).

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 645796, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -1362637.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 5.84
Average Volume: 15061.3
30-Day High: 6.13
30-Day Low: 4.72

[Detailed Financials: Q3 2025]
- Total Assets: $12,543,202.00
- Total Liabilities: $1,311,503.00
- Total Equity: $11,231,699.00
- Current Assets: $6,191,602.00
- Current Liabilities: $1,247,786.00

[Income Statement: Q3 2025]
- Revenue: $645,796.00
- Net Income: $-1,362,637.00
- Gross Profit: $191,029.00
- Operating Income: $-1,426,841.00
- Earnings Per Share (EPS): -0.12

[Cash Flow Statement: Q3 2025]
- Net Cash Flow: $-1,061,780.00

[Detailed Financials: Q2 2025]
- Total Assets: $13,633,709.00
- Total Liabilities: $1,172,723.00
- Total Equity: $12,460,986.00
- Current Assets: $7,248,073.00
- Current Liabilities: $1,103,590.00

[Income Statement: Q2 2025]
- Revenue: $442,830.00
- Net Income: $-1,705,465.00
- Gross Profit: $101,558.00
- Operating Income: $-1,409,742.00
- Earnings Per Share (EPS): -0.15

[Cash Flow Statement: Q2 2025]
- Net Cash Flow: $-1,587,773.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Nutriband (NTRB).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Nutriband.

2) MARKET_SCORE[]
This conversation was initiated because NTRB is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for NTRB.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, NTRB could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect NTRB to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Nutriband.

11) ETHICAL_RATING[]
Rate Nutriband’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Nutriband.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

NTRB_IN_29 [2025-04-29 08:36:51 -0400] 126 Bytes | 29 tokens | Cum: 6495 tkns (81.19% of 8k)
==========================================================================

====================================
[2025-04-29 08:36:51] # Analysis Completed
Elapsed Time: 21.74 seconds